SEARCH

SEARCH BY CITATION

References

  • Beaulieu J. M. and Gainetdinov R. R. (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 63, 182217.
  • Bezard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C. and Sokoloff P. (2003) Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med. 9, 762767.
  • Boundy V. A., Luedtke R. R., Gallitano A. L., Smith J. E., Filtz T. M., Kallen R. G. and Molinoff P. B. (1993) Expression and characterization of the rat D3 dopamine receptor: pharmacologic properties and development of antibodies. J. Pharmacol. Exp. Ther. 264, 10021011.
  • Caccia S., Invernizzi R. W., Nobili A. and Pasina L. (2013) A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Ther. Clin. Risk Manag. 9, 319328.
  • Caine S. B. and Koob G. F. (1993) Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 260, 18141816.
  • Cheng Y. and Prusoff W. H. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 30993108.
  • Cheung T. H. C., Nolan B. C., Hammerslag L. M., Wever S. M., Durbub H., Peartree N. A., Mach R. H., Luedtke R. R. and Neisewander J. L. (2012) Novel phenylpiperazines derivatives with selectivity for dopamine D3 receptors modulate cocaine self-administration in rats. Neuropharmacology 63, 13461359.
  • Cheung T. H., Loriaux A. L., Weber S. M., Chandler K. N., Lenz J. D., Schaan R. F., Mach R. H., Luedtke R. R. and Neisewander J. L. (2013) Reduction of cocaine self-administration and D3 receptor-mediated behavior by two novel dopamine D3 receptor-selective partial agonists, OS-3-106 and WW-III-55. J. Pharmacol. Exp. Ther. 347, 410423.
  • Chien E. Y., Liu W., Zhao Q. et al. (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330, 10911095.
  • Chio C. L., Lajiness M. E. and Huff R. M. (1994) Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol. Pharmacol. 45, 5160.
  • Corvol J. C., Valjent E., Pascoli V., Robin A., Stipanovich A., Luedtke R. R., Belluscio L., Girault J. A. and Herve D. (2007) Quantitative changes in galphaolf protein levels, but not D1 receptor, alter specifically acute responses to psychostimulants. Neuropsychopharmacology 32, 11091121.
  • Denys D., de Vries F., Cath D. et al. (2013) Dopaminergic activity in tourette syndrome and obsessive-compulsive disorder. Eur. Neuropsychopharmacol. 23, 14231431.
  • Emilien G., Maloteaux J. M., Geurts M., Hoogenberg K. and Cragg S. (1999) Dopamine receptors–physiological understanding to therapeutic intervention potential. Pharmacol. Ther. 84, 133156.
  • Erritzoe D., Tziortzi A., Bargiela D. et al. (2014) In vivo imaging of cerebral dopamine d3 receptors in alcoholism. Neuropsychopharmacology 39, 17031712.
  • Fuxe K., Hokfelt T., Olson L. and Ungerstedt U. (1977) Central monoaminergic pathways with emphasis on their relation to the so called ‘extrapyramidal motor system. Pharmacol. Ther. B 3, 169210.
  • Giros B., Martres M. P., Sokoloff P. and Schwartz J. C. (1990) Gene cloning of human dopaminergic D3 receptor and identification of its chromosome. C. R. Acad. Sci. III 311, 501508.
  • Gottwald M. D. and Aminoff M. J. (2008) New frontiers in the pharmacological management of parkinson's disease. Drugs Today 44, 531545.
  • Hall H., Hogberg T., Halldin C., Bengtsson S. and Wedel I. (1991) Synthesis and binding properties of the fluorinated substituted benzamide [3H]NCQ 115, a new selective dopamine D2 receptor ligand. Eur. J. Pharmacol. 201, 110.
  • Hillefors M. and von Euler G. (2001) Pharmacology of [3H]R(+)-7-OH-DPAT binding in the rat caudate-putamen. Neurochem. Int. 38, 3142.
  • Kim O. J., Gardner B. R., Williams D. B., Marinec P. S., Cabrera D. M., Peters J. D., Mak C. C., Kim K. M. and Sibley D. R. (2004) The role of phosphorylation in D1 dopamine receptor desensitization: evidence for a novel mechanism of arrestin association. J. Biol. Chem. 279, 79998010.
  • Kumar R., Riddle L., Griffin S. A., Grundt P., Newman A. H. and Luedtke R. R. (2009) Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology 56, 944955.
  • Kuzhikandathil E. V., Yu W. and Oxford G. S. (1998) Human dopamine D3 and D2L receptors couple to inward rectifier potassium channels in mammalian cell lines. Mol. Cell. Neurosci. 12, 390402.
  • Leff S. E. and Creese I. (1985) Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor. Mol. Pharmacol. 27, 184192.
  • Levant B. (1997) The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev. 49, 231252.
  • Luedtke R. R., Freeman R. A., Boundy V. A., Martin M. W. and Mach R. H. (2000) Characterization of 125I-IABN, a novel azabicyclononane benzamide selective for D2-like dopamine receptors. Synapse 38, 438449.
  • Luedtke R. R., Mishra Y., Griffin S. A., Bell-Horner C., Taylor M., Vangveravong S., Dillon G., Reichert D. E. and Mach R. H. (2012) Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds. ACS Chem. Neurosci. 3, 10501062.
  • Mach R. H., Tu Z., Xu J., Li S., Jones L. A., Taylor M., Luedtke R. R., Derdeyn C. P., Perlmutter J. S. and Mintun M. A. (2011) Endogenous dopamine (DA) competes with the binding of a radiolabeled D(3) receptor partial agonist in vivo: a positron emission tomography study. Synapse 65, 724732.
  • McGonigle P. and Molinoff P. B. (1989) Quantitative aspects of drug-receptor interactions, Chapter 9 in Basic Neurochemistry (Siegel G. J., Agranoff B. W., Albers R. W. and Molinoff P. B., eds), pp. 545572. Raven Press, New York.
  • Missale C., Nash S. R., Robinson S. W., Jaber M. and Caron M. G. (1998) Dopamine receptors: from structure to function. Physiol. Rev. 78, 189225.
  • Monsma F. J., Jr, Mahan L. C., McVittie L. D., Gerfen C. R. and Sibley D. R. (1990) Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc. Natl Acad. Sci. USA 87, 67236727.
  • Nakajima S., Gerretsen P., Takeuchi H., Caravaggio F., Chow T., Le Foll B., Mulsant B., Pollock B. and Graff-Guerrero A. (2013) The potential role of dopamine D receptor neurotransmission in cognition. Eur. Neuropsychopharmacol. 23, 799813.
  • Neve K. A. (1991) Regulation of dopamine D2 receptors by sodium and pH. Mol. Pharmacol. 39, 570578.
  • Neve K. A., Henningsen R. A., Kinzie J. M., De Paulis T., Schmidt D. E., Kessler R. M. and Janowsky A. (1990) Sodium-dependent isomerization of dopamine D-2 receptors characterized using [125I]epidepride, a high-affinity substituted benzamide ligand. J. Pharmacol. Exp. Ther. 252, 11081116.
  • Neve K. A., Cumbay M. G., Thompson K. R., Yang R., Buck D. C., Watts V. J., DuRand C. J. and Teeter M. M. (2001) Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor. Mol. Pharmacol. 60, 373381.
  • Newman A. H., Beuming T., Banala A., Levy B., Okunola O., Cao J., Luedtke R. R., Stevens R., Javitch J. A. and Shi L. (2012) Molecular determinants of selectivity and efficacy at the dopamine D3 receptor (D3R). J. Med. Chem. 55, 66896699.
  • Nishi A., Snyder G. L. and Greengard P. (1997) Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J. Neurosci. 17, 81478155.
  • Nord M. and Farde L. (2011) Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci. Ther. 17, 97103.
  • Park B. H., Fishburn C. S., Carmon S., Accili D. and Fuchs S. (1995) Structural organization of the murine D3 dopamine receptor gene. J. Neurochem. 64, 482486.
  • Park S. W., Seo M. K., Cho H. Y., Lee J. G., Lee B. J., Seol W. and Kim Y. H. (2011) Differential effects of amisulpride and haloperidol on dopamine D2 receptor-mediated signaling in SH-SY5Y cells. Neuropharmacology 61, 761769.
  • Payer D., Balasubramaniam G. and Boileau I. (2014a) What is the role of the D3 receptor in addiction? A mini review of PET studies with [11C]-(+)-PHNO. Prog. Neuropsychopharmacol. Biol. Psychiatry 52, 48.
  • Payer D. E., Behzadi A., Kish S. J. et al. (2014b) Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [11C]-(+)-PHNO. Neuropsychopharmacology 39, 311318.
  • Sanchez-Pernaute R., Jenkins B. G., Choi J. K., Iris Chen Y. C. and Isacson O. (2007) In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias. Neurobiol. Dis. 27, 220227.
  • Scatchard G. (1949) The attractions of proteins for small molecules and ions. Ann. N. Y. Acad. Sci. 51, 662672.
  • Sokoloff P., Giros B., Martres M. P., Bouthenet M. L. and Schwartz J. C. (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347, 146151.
  • Sternweis P. C. and Smrcka A. V. (1992) Regulation of phospholipase C by G proteins. Trends Biochem. Sci. 17, 502506.
  • Tu Z., Li S., Cui J., Xu J., Taylor M., Ho D., Luedtke R. R. and Mach R. H. (2011) Synthesis and pharmacological evaluation of fluorine-containing D(3) dopamine receptor ligands. J. Med. Chem. 54, 15551564.
  • Tziortzi A. C., Searle G. E., Tzimopoulou S., Salinas C., Beaver J. D., Jenkinson M. M., Laruelle M., Rabiner E. A. and Gunn R. N. (2011) Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. NeuroImage 54, 264277.
  • Urs N. M., Daigle T. L. and Caron M. G. (2011) A dopamine D1 receptor-dependent beta-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice. Neuropsychopharmacology 36, 551558.
  • Vangveravong S., McElveen E., Taylor M., Xu J., Tu Z., Luedtke R. R. and Mach R. H. (2006) Synthesis and characterization of selective dopamine D2 receptor antagonists. Bioorg. Med. Chem. 14, 815825.
  • Vangveravong S., Zhang Z., Taylor M., Bearden M., Xu J., Cui J., Wang W., Luedtke R. R. and Mach R. H. (2011) Synthesis and characterization of selective dopamine D2 receptor ligands using aripiprazole as the lead compound. Bioorg. Med. Chem. 19, 35023511.
  • Wang Q., Mach R. H., Luedtke R. R. and Reichert D. E. (2010) Subtype selectivity of dopamine receptor ligands: insights from structure and ligand-based methods. J. Chem. Inf. Model. 50, 19701985.
  • Wollemann M. (1980) Receptors acting through adenylate cyclase in the CNS. Acta Physiol. Acad. Sci. Hung. 55, 299304.
  • Yan Z., Feng J., Fienberg A. A. and Greengard P. (1999) D2 dopamine receptors induce mitogen-activated protein kinase and cAMP response element-binding protein phosphorylation in neurons. Proc. Natl Acad. Sci. USA 96, 1160711612.
  • Zhou G., Wong M.-T. and Zhou G.-Q. (1983) Diffusion-controlled reactions of enzymes: an approximate analytic solution of Chou's model. Biophys. Chem. 18, 125132.